Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Hailed as the first Chinese company to launch a homegrown antibody drug conjugate (ADC), RemeGen has recently been battling a ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Kyle Mach joined Sullivan & Cromwell's antitrust practice after over a year with the Federal Trade Commission.

Zai Lab Limited today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...